Feasibility and effectiveness of inhaled carboplatin in NSCLC patients
- 8 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 30 (4), 1628-1640
- https://doi.org/10.1007/s10637-011-9714-5
Abstract
Background Inhaled chemotherapy is under investigation as an alternative therapeutic modality for Non-Small Cell Lung Cancer. Methods 60 NSCLC patients were randomized into 3 groups in this study. 20/60 patients (group A—control group) received I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1); 20/60 (group B) received 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1); and 20/60 (group C) received all the predicted I.V. dose of carboplatin as aerosol in 3 equally divided fractions D1-3. In all patients I.V. docetaxel 100/m2 was as well administered (D1). Lung functional tests were performed in all groups before chemotherapy in the 3rd and 6th cycles. Results Group B had a statistically significant increase in survival compared to control group A [275 days (95% CI 249–300) vs. 211 (95% CI 185–236)]. In regard to lung functional tests, a statistically significant decline was observed only in FEV1 of group C in 6 months compared to the initial measurement. Conclusions Inhaled carboplatin could be given as an alternative root of pulmonary drug delivery in selected patients, but further randomized studies remain to prove whether the inhaled chemotherapy is an efficient and safe treatment modality.Keywords
This publication has 80 references indexed in Scilit:
- Determination of carboplatin in canine plasma by high‐performance liquid chromatographyBiomedical Chromatography, 2010
- The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and designBMC Cancer, 2010
- Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2010
- Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxelEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Office-Based Intraperitoneal Chemotherapy for Ovarian CancerJournal of Oncology Practice, 2008
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Prognostic Factors for Short-term Survival in Patients with Stage IV Non-small Cell Lung CancerJapanese Journal of Cancer Research, 1999
- Cisplatin administered by the intracavitary route as treatment for malignant mesotheliomaCancer, 1986